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The rationale for Multilevel Educational 
and Motivational Intervention in 
Patients after Myocardial Infarction 
(MEDMOTION) project is to support 
multicentre randomized clinical trial 
Evaluating Safety and Efficacy of 
Two Ticagrelor-based De-escalation 
Antiplatelet Strategies in Acute Coronary 
Syndrome (ELECTRA – SIRIO 2)
ABSTRACT
The Multilevel Educational and Motivational Intervention in Patients after Myocardial Infarction (MEDMOTION) 
project will be adopted to support adherence to the study treatment in the Evaluation Safety and Efficacy of 
Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome (ELECTRA-SIRIO 
2) a randomized clinical trial.
A prespecified sub-analysis of the ELECTRA-SIRIO 2 trial will be performed to evaluate the impact of the 
results of MEDMOTION diagnostic questionnaires on the clinical outcomes. 
The study population will comprise of 4,500 patients consecutively admitted to the study centres due to acute 
coronary syndrome. The MEDMOTION project involves the following interventions: patients’ education,
motivation, reminding to take medications and to attend consecutive medical appointments. Dedicated 
questionnaires will be applied to diagnose study participants with regard to their readiness for discharge 
from the hospital at the end of initial hospitalization, the risk of non-adherence to the medication at the end 
of 3rd and 12th month of follow up, and the functioning in disease at the end of 3rd and 12th month of follow 
up. The primary safety composite endpoint of this study is type 2, 3 or 5 bleeding according to the BARC 
criteria, occurring during the first 12 months after ACS. The primary efficacy endpoint is the composite of 
death from any cause, the first nonfatal MI, or the first nonfatal stroke. The key secondary endpoint, net 
clinical effect, was defined as the composite of death from any cause, a nonfatal MI or a nonfatal stroke, 
and the first occurrence of BARC type 2, 3, or 5 bleeding. 
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Concluding, it is expected that the comprehensive approach designed in the MEDMOTION project, in-
cluding use of diagnostic questionnaires, will significantly contribute to obtaining a high level of adherence 
to medication and improving clinical outcomes in the ELECTRA-SIRIO 2 trial. 
Key words: acute coronary syndrome, adherence to medication, functioning in chronic illness, ticagrelor, 
antiplatelet treatment
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The World Health Organization (WHO) defines “ad-
herence” as “the extent to which a person’s behaviour 
including taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed 
recommendations from a health care provider” [1]. 
According to the Food and Drug Administration data, 
from 30 to 50% of patients do not exactly adhere to rec-
ommendations received from their healthcare providers, 
which significantly increases the risk of unfavourable 
clinical outcome [2–5, 22, 24–26]. The enhancement 
of medication adherence is usually accompanied by 
the elimination of unfavourable dietary habits and 
improvement in physical activity [6–10, 20]. Good 
adherence to medication is a pivotal factor for reliable 
evaluation of new drugs and new treatment strategies 
tested in clinical trials [37]. Therefore, the Multilevel 
Educational and Motivational Intervention in Patients 
After Myocardial Infarction (MEDMOTION) project will 
be adopted to support adherence to the study treatment 
in the Evaluation of Safety and Efficacy of Two Ticagre-
lor-based De-escalation Antiplatelet Strategies in Acute 
Coronary Syndrome (ELECTRA-SIRIO 2) a randomized 
clinical trial. 
The ELECTRA-SIRIO 2 trial aims to evaluate the 
safety and efficacy of ticagrelor dose reduction with or 
without the continuation of aspirin versus DAPT with 
standard-dose ticagrelor, in reducing clinically relevant 
bleeding and in maintaining anti-ischaemic efficacy 
in ACS patients. The trial was designed as a phase 
III, randomised, multicentre, double-blind, investiga-
tor-initiated clinical study with a 12-month follow-up. 
Up to 35 centres are expected to participate in the trial. 
The study population will comprise of 4,500 patients 
consecutively admitted to the study centres due to 
ACS, including patients with ST-elevation myocardial 
infarction, non-ST-elevation myocardial infarction and 
unstable angina [35]. All study participants will be 
randomized during hospitalization for the index ACS 
into one of three arms: low-dose ticagrelor with aspirin 
group, low-dose ticagrelor with the placebo group, 
and the control arm treated with standard-dose tica-
grelor with aspirin. All patients enrolled into this trial 
are expected to undergo 5 out-patient follow-up visits 
(1, 3, 6, 9 and 12 months after the index ACS), during 
which they will undergo the assessment of the study 
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Background endpoints and careful evaluation of adherence to the 
study treatment based on tablets counting at follow-up 
visits. Moreover, in line with the MEDMOTION project, 
dedicated questionnaires will be applied to diagnose 
study participants with regard to their readiness for 
discharge from the hospital at the end of initial hospi-
talization, the risk of non-adherence to the medication 
at the end of 3rd and 12th month of follow up, and the 
functioning in disease at the end of 3rd and 12th month 
of follow up. The primary safety composite endpoint of 
this study is type 2, 3 or 5 bleeding according to the 
BARC criteria, occurring during the first 12 months after 
ACS. The primary efficacy endpoint is the composite 
of death from any cause, the first nonfatal MI, or the 
first nonfatal stroke. The key secondary endpoint, net 
clinical effect, was defined as the composite of death 
from any cause, a nonfatal MI or a nonfatal stroke, and 
the first occurrence of BARC type 2, 3, or 5 bleeding. 
A prespecified sub-analysis of the ELECTRA-SIRIO 
2 trial will be performed to evaluate the impact of the 
results of MEDMOTION diagnostic questionnaires on 
the clinical outcomes. 
Methods
Project design
The MEDMOTION project involves the following 
interventions: patients’ education, motivation, reminding 
to take medications and to attend consecutive medical 
appointments. Furthermore, questionnaire-based diag-
noses of readiness to discharge from hospital, adher-
ence to treatment, and functioning in chronic disease 
are essential parts of this project [38].
MEDMOTION interventions
Patients’ education 
The educational interventions are aimed to improve 
the knowledge and practical skills of both patients 
after ACS and their cohabitating family members [14, 
40, 43]. It is assumed that individualized, complex ed-
ucation started during hospitalisation and continued 
after discharge, which would include explaining the 
pathophysiology, symptoms and prevention of coronary 
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artery disease, elucidating goals and potential benefits 
of treatment, as well as highlighting the risk of prema-
ture termination of therapy, with the use of additional 
methods helping patients to remember the treatment 
schedule, will enhance adherence to treatment [44]. 
The education mentioned above will be standard-
ized, i.e. based on a series of brochures Reach for 
Health developed for the MEDMOTION project, and at 
the same time individualized as a set of brochures in 
one workbook will be selected individually depending 
on patients’ needs. 
The following Reach for Health brochures have been 
included in the protocol of ELECTRA – SIRIO 2 trial: 
1. Reach for knowledge – coronary artery disease, 
myocardial infarction by Kubica A and Umińska JM
2. Woman, reach for health by Jasiewicz M
3. Reach for medication Umińska JM and Kubica J
4. Reach for knowledge – hypertension by Sulikowska 
B, Donderski R
5. Reach for knowledge – diabetes mellitus by Umińs-
ka JM
6. Reach for knowledge about nutrition by Michalski P
7. Reach for physical activity by Kleinrok A and Derew-
iecki T
8. Do not reach for a cigarette by Czarnecki D, Ziół-
kowski M.
The series of brochures Reach for Health is supple-
mented by a patient self-control diary. 
Apart from the brochures included into ELECTRA 
– SIRIO 2 trial protocol, two additional brochures were 
developed for the MEDMOTION project:
1. Reach for knowledge – stroke by Ulaszewska K, 
Grzechowiak E, and Kozera G
2. Reach for physical activity after stroke by Szeremeta 
E
All brochures have a similar structure, starting with 
a brief chapter entitled: Do you know that ...? – con-
taining the most interesting facts designed to grab the 
reader’s attention. The main part provides the patient 
with important information in an accessible, illustrated 
form. The brochure ends with take-home messages 
and answers to common questions.
Verbal education of patients related to the content of 
brochures will be started during the initial hospitalization 
period and continued during five scheduled follow-up 
visits. A set of individually selected brochures will be 
given to the patient during the initial hospitalization.
Patients’ motivation 
Patients’ education will be supported by motiva-
tional interventions [41]. The motivational interview 
will be conducted by healthcare staff during the initial 
hospitalization period and follow-up visits. The moti-
vational interview is a widely used, scientifically tested 
and clinically relevant method of patient counselling 
developed by Miller and Rollnick [49,50]. Effective 
application of both in-hospital motivational interview 
as well as post-discharge behavioural interventions 
(telephone-based, text messages) for cardiovascular 
prevention have been already reported [51–57]. In 
essence, the motivational interview promotes partner-
ship-oriented counselling interventions of healthcare 
staff with the patient. Change elicitation results from 
evoking the patient’s intrinsic motivation for behavioural 
change by drawing on personally meaningful goals. The 
patient’s autonomy is fully respected, which entails shift-
ing the decision to implement behavioural changes and 
the responsibility of change implementation outcomes 
from the medical staff to the patient. The motivational 
interview should be conducted by medical staff with 
empathy, emphasizing the discrepancy between the 
current state and the patients’ future well-being, ‘rolling’ 
with patients’ resistance to change and bolstering their 
self-efficacy and self-regulation [58].
The key assumptions of Motivational Interview thus 
comprise, firstly, a non-judgemental approach to the 
patient’s perspective and active interest to understand 
how the situation is perceived through the patient’s 
eyes (active empathy). Secondly, it involves focusing on 
the gap existing between the patient’s current and the 
expected behavioural patterns (develop discrepancy) 
to identify the starting point for future change imple-
mentation, which, importantly, is to be initiated by the 
patient rather than the therapist. The fact that it is the 
patient who is to identify the need for change should 
minimize the chance of an argument and resistance 
(avoid argument). Once the patient agrees to implement 
behavioural changes, it can be expected that the patient 
will have to deal with several ambivalent periods that 
will need assistance and problem-solving measures 
(rolling with resistance). The main role of the therapist’s 
in such periods will be to reinforce the patient’s capacity 
of self-direction, i.e. the conviction that he can deal with 
the problems himself (self-efficacy). Given the adequate 
therapeutic conditions, a patient is expected to evolve 
and enhance his health-oriented behavioural patterns 
with the therapist’s gentle guidance and reinforcement 
of proper changes. The main idea of motivational inter-
viewing is thus not to coerce and control but to guide 
and support. 
Reminding patients to take medications and 
attend consecutive medical appointments
In order to increase protocol adherence and pa-
tient retention, a  convenient, intuitive data collection 
interface available for patients as an online and mobile 
platform will be used in the MEDMOTION project. The 
main features of this supporting software are to inform 
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and guide patients with clear instructions managing the 
visit calendar: reminders about the date and place of 
the control visit; information on what to bring to the visit 
and also to make an unplanned visit in case of urgent 
necessity. The system will also provide support to the 
patient with every day reminding of the need to regu-
larly take drugs and it will provide patients with relevant 
educational content. Moreover, a patient diary, allowing 
him to report any adverse events will be available.
MEDMOTION questionnaire-based 
diagnoses
Diagnosis of readiness to discharge from hospital 
The Readiness for Hospital Discharge after Myo-
cardial Infarction Scale (RHD-MIS) was designed for 
subjects after myocardial infarction [21,39,46,48]. The 
questionnaire consists of 23 questions: the subjective 
assessment of patients’ knowledge includes 7 items, 
patient’s expectations comprise 9 items, and 7 items 
are dedicated to the objective assessment of patients’ 
knowledge. The RHD-MIS was validated in patients 
recovered for ACS and treated with the percutaneous 
coronary intervention. The internal consistency of the 
entire questionnaire was confirmed by the alpha-Cron-
bach coefficient of 0.789. The RHD-MIS fulfilled the 
assumption of factor analysis: the determinant of 
the correlation matrix was 0.001, Kaiser-Mayer-Olkin 
(K-M-O) statistic was 0.723, and the Bartlett’ test of 
sphericity was statistically significant. The analysis of 
the internal consistency of the three areas confirmed 
the rightness of distinguishing three subscales [48]. 
Diagnosis of adherence to treatment 
Apart from the intention-to-treat analysis, the 
on-treatment analysis of the trial outcome is planned, 
therefore accurate evaluation of adherence in neces-
sary. There is no gold standard, nor a universal tool 
which could evaluate the level of adherence; therefore, 
direct (tablets counting at follow-up visits) and indirect 
method (the Adherence in Chronic Diseases Scale 
– ACDS) will be applied in the ELECTRA-SIRIO 2 trial. 
The ACDS was validated and subsequently ap-
plied to patients after myocardial infarction [23]. It 
was designed to identify patients of a high risk of low 
adherence, as well as beliefs, barriers and behaviour 
related to medication adherence [44]. The internal con-
sistency of the ACDS final 7 items version was assessed 
using Cronbach’s alpha coefficient, and the value of 
0.752 confirmed high reliability and homogeneity of 
the questionnaire. The determinant of the correlation 
matrix was 0.211, the value of K-M-O statistic was 
0.848 and Bartlett’s test of sphericity was statistically 
significant [19]. The ACDS indicating subjects of the 
high risk of low adherence has the potential to improve 
patient — a health care professional communication 
and relationship, which are the key points providing 
higher adherence to the specific therapy. 
Diagnosis of functioning in chronic disease 
The Functioning in Chronic Illness Scale (FCIS) has 
been designed to evaluate the impact of the disease 
on the patient, the patients’ impact on the disease and 
the impact of the disease on patients’ attitudes [42]. It 
is the first and only available tool allowing a compre-
hensive assessment of physical and mental functioning 
dedicated to patients with chronic diseases. The FCIS 
was validated in patients with coronary artery disease 
treated with PCI. The questionnaire consists of 24 ques-
tions and it is divided into three subscales. The value of 
the a-Cronbach coefficient for the entire questionnaire 
was 0.855 indicating that the questionnaire is reliable 
and homogenous. The value of the determinant of the 
correlation matrix was 0.001, K-M-O parameter was 
0.843 and the Bartlett’ test of sphericity was statistically 
significant [42]. The assessment of various aspects 
of patients’ functioning with FCIS allows diagnosing 
deficit areas to implement appropriate therapeutic and 
educational interventions. 
Discussion
Poor adherence to medication is known to 
deteriorate clinical outcome in patients after ACS 
[13,27,28,32,34]. Ensuring good adherence is also 
a critical issue in randomized clinical trials evaluating 
treatment strategies, as the intention-to-treat analysis, 
i.e. with the inclusion of all patients according to the 
randomly assigned trial group, irrespective of the actual 
treatment received, is a widely accepted method for 
such kind of studies [36]. Poor adherence to the eval-
uated treatment may lead to a serious result bias. To 
estimate this bias, the on-treatment analysis should 
supplement the results; however, to perform such an 
analysis knowledge of actual adherence recorded for 
each patient is essential [11, 12]. Therefore, to ensure 
the highest quality and reliability of results the MED-
MOTION project was included in the ELECTRA-SIRIO 
2 trial. Patients’ self-reported drug intake is an unreliable 
method of adherence evaluation [12, 29–32]; therefore, 
tablets counting at follow-up visits will additionally 
be applied.
Diverse interventions aimed to ameliorate the adher-
ence to medication planned in the MEDMOTION project, 
including education, motivation, and “reminders” [15, 
16, 47], will be supported by a comprehensive, multi-
stage assessment of patients, which should improve 
248
MEDICAL RESEARCH JOURNAL 2020. vol. 5. no. 4
www.journals.viamedica.pl/medical_research_journal
the quality of medical care by personalizing these inter-
ventions in patients enrolled into the ELECTRA-SIRIO 
2 trial [17, 18, 33]. The Readiness for Hospital Discharge 
after Myocardial Infarction Scale (RHD-MIS) [48] was 
designed for in-hospital evaluation, while the Adherence 
in Chronic Diseases Scale (ACDS) [19, 23] and the 
Functioning in Chronic Illness Scale (FCIS) [42] was 
meant for examination during follow-up visits. It was 
developed as a tool aimed to improve the quality of the 
discharge process, including additional personalized 
education and motivation. All the presented tools were 
expected to reflect the effectiveness of different aspects 
of patient-medical staff collaboration and were tested in 
patients with coronary artery disease after ACS treated 
with PCI [19, 42, 45, 46].
Concluding, it is expected that the comprehensive 
approach designed in the MEDMOTION project, includ-
ing use of diagnostic questionnaires, will significantly 
contribute to obtaining a high level of adherence to 
medication and improving clinical outcomes in the 
ELECTRA-SIRIO 2 trial. 
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